checkAd

     145  0 Kommentare MDxHealth Successfully Completes a EUR 25.0 Million (USD 30.4 Million)(1) Capital Increase

    THIS ANNOUNCEMENT IS NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD BE PROHIBITED BY APPLICABLE LAW

    NEWS RELEASE – REGULATED INFORMATION – INSIDE INFORMATION
    21 January 2021, 11:30 p.m. CET

    IRVINE, CA, and HERSTAL, BELGIUM – 21 January 2021 – MDxHealth SA (Euronext Brussels: MDXH) (the "Company" or "MDxHealth"), a commercial-stage innovative molecular diagnostics company, announces the successful pricing of its capital increase with the offering of new ordinary shares. The Company raised EUR 25.0 million (USD 30.4 million)(1) in gross proceeds by means of a private placement of 27,777,777 new shares (being approximately 30.63% of the Company's outstanding shares) at an issue price of EUR 0.90 per share through an accelerated bookbuild offering (the "Capital Increase").

    Michael McGarrity, CEO of MDxHealth, said: "We are pleased to have secured additional funding from a high quality mix of U.S. and European investors. This financing allows us to continue to advance our focus on commercial execution, operating discipline and advancing our menu in the diagnosis and treatment of prostate cancer. We look forward to providing our full year 2020 operating and financial results and a view forward for 2021 on 3 March 2021."

    The net proceeds of the Capital Increase will be used to drive further commercial focus and execution, to advance the Company’s corporate strategy and for general corporate purposes.

    The payment and delivery of the new shares to be issued in the Capital Increase is expected to take place on 26 January 2021.

    KBC Securities is acting as Sole Global Coordinator and together with Oppenheimer & Co. as Joint Bookrunners for the Capital Increase.

    Lesen Sie auch

    As announced earlier, Biovest, Valiance and MVM (the "Pre-Committing Shareholders"), each an important shareholder of the Company, pre-committed to submit orders in the offering. In line with these pre-commitments, 13,386,111 shares were allocated to the Pre-Committing Shareholders.

    The new shares to be issued will have the same rights and benefits as, and rank pari passu in all respects, including as to entitlement to dividends and distributions, with, the existing and outstanding shares of MDxHealth at the moment of their issuance and will be entitled to distributions in respect of which the relevant record date or due date falls on or after the date of issue of the new shares.

    Seite 1 von 6



    globenewswire
    0 Follower
    Autor folgen

    Verfasst von globenewswire
    MDxHealth Successfully Completes a EUR 25.0 Million (USD 30.4 Million)(1) Capital Increase THIS ANNOUNCEMENT IS NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD BE PROHIBITED BY APPLICABLE LAW NEWS RELEASE – REGULATED …